Latest filing published 25 Aug 2023 for Sprint Bioscience AB, €2,745.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Mathias Skalmstad: trading record in brief
Mathias Skalmstad discloses dealings in Sprint Bioscience AB to Finansinspektionen. In total, 3 filings cover trades dated from 7 September 2021 to 25 August 2023.
On the market, this insider has only ever bought: 2 purchases, €2,910 in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. So far in 2023, the count stands at 2 purchases and no sales.
The newest entry dates from 25 August 2023: an open-market purchase of €2,745, in Sprint Bioscience AB. Most trades are made public on the day they happen. Under the Market Abuse Regulation, managers have three business days to notify their trades. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Companies and markets linked to Mathias Skalmstad
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 32,000 shares@ SEK 1.0221.3% of flowAktieISIN SE0006343745FI:csv-097a35e59daf8d0c43e2Canonical exit: 23 Nov 2023 (T+90)
- 2,000 shares@ SEK 0.981.3% of flowAktieISIN SE0006343745FI:csv-332a1b4dec8a393c37e8Canonical exit: 23 Nov 2023 (T+90)
- 19,000 shares@ SEK 5.3477.4% of flowBTA (betald tecknad aktie)ISIN SE0016609804FI:csv-e7601f9542971d950d9e
3 of 3 declarations